Harbin Pharmaceutical Group Co., Ltd. (SHSE: 600664)

About Harbin Pharmaceutical Group Co., Ltd.

Harbin Pharmaceutical Group Co., Ltd. functions as a leading pharmaceutical company, overseeing the complete process from drug discovery and development to manufacturing and global sales. The firm's activities span both domestic Chinese markets and international territories. Its business structure is segmented into seven key areas: Antibiotics, Small-Molecule Drug Formulations, Over-the-Counter (OTC) and Health Products, Modern Chinese Medicine, Biopharmaceutical products, Animal Vaccines, and Pharmaceutical Distribution services. The company's broad product portfolio features a comprehensive selection of penicillin and cephalosporin antibiotics, in addition to vital pharmaceutical intermediates. Its notable offerings include various types of injections, such as Shuang Huanglian and Danshen freeze-dried injections, alongside a wide array of oral medications like roxithromycin dispersible tablets, amoxicillin capsules, and specialized pediatric granules containing paracetamol. The product line also encompasses a diverse range of antibiotics, highlighted by multiple cephalosporin-based injections (e.g., ceftriaxone sodium, cefepime hydrochloride) and penicillin derivatives, alongside extracts from traditional Chinese medicine like Panax ginseng. Furthermore, the group manufactures essential medical protective gear, including disposable surgical and protective masks, as well as isolation and protective gowns. These products are distributed under numerous well-known brands, including Hongyan Yaopin, Guangwei, Renmin Tongtai, and Hayao, among others. The company's headquarters are located in Harbin, China.

ISIN

CNE0000009T3

Founded

1991

Listed since

Jun 29, 1993

Exchange

Shanghai Stock Exchange

Currency

CNY